Probiotic agents in the treatment of irritable bowel syndrome

Journal of International Medical Research

Volumn 35, Issue 5, 2007, Pages 583-589

  Guslandi, M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Intestinal flora; Irritable bowel syndrome; Probiotics

Indexed keywords

NEOMYCIN; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; UNCLASSIFIED DRUG; VSL 3;

BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM DETECTION; BIFIDOBACTERIUM; CLINICAL FEATURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FECES ANALYSIS; FOLLOW UP; FUNGAL STRAIN; GASTROENTERITIS; HISTOPATHOLOGY; HUMAN; INFECTIOUS DIARRHEA; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS; MICROBIAL ACTIVITY; MICROFLORA; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; SACCHAROMYCES BOULARDII; STREPTOCOCCUS THERMOPHILUS; SYMPTOM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 35348813731     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000703500501     Document Type: Review

References (45)

1. Mertz HR: Irritable bowel syndrome. N Engl J Med 2003; 349: 2136-2146.
2. Cash BD, Chey WD: Irritable bowel syndrome: a systematic review. Clin Fam Pract 2004; 6: 647-699.
3. Wilson S, Roberts L, Roalfe A, et al: Prevalence of irritable bowel syndrome: a community survey. Br J Clin Pract 2004; 54: 495-502.
4. Jailwala J, Imperiale TF, Kroenke K: Pharmacological treatment of the irritable bowel syndrome: a systematic review of randomized controlled trials. Ann Int Med 2000; 133: 136-147.
5. Halvorson H, Schlett CD, Riddle MS: Postinfectious irritable bowel-a meta-analysis. Am J Gastroenterol 2006; 101: 1-6.
6. Rodriguez LAG, Ruigomez A: Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999; 318: 565-566.
7. Lin HC: Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292: 852-858.
8. 2 breath test. Am J Gastroenterol 2005; 100: 1566-1570.
9. Balsari A, Ceccarelli A, Dubini F, et al: The fecal microbial population in irritable bowel syndrome. Microbiologica 1982; 5: 185-194.
10. Si JM, Yu YC, Fan YJ, et al: Intestinal microbiology and quality of life in irritable bowel syndrome. World J Gastroenterol 2004; 10: 1802-1805.
11. Malinen E, Rintilla T, Kajander K, et al: Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373-382.
12. Madden JAJ, Plummer S, Sen S, et al: Comparison of the caecal and faecal microflora of healthy subjects and patients with irritable bowel syndrome. Gut 2001; 48 (suppl 1): A58.
13. Koide A, Yamaguchi T, Odaka T, et al: Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 1735-1741.
14. King TS, Elia M, Hunter JO: Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352: 1187-1189.
15. Serra J, Apziroz F, Malagelada JR: Impaired transit and tolerance of intestinal gas in irritable bowel syndrome. Gut 2001; 48:14-19.
16. Spiller RC: Infection, immune function and functional gut disorders. Clin Gastroenterol Hepatol 2004; 2: 445-455.
17. Gwee KA, Collins SM, Read NW, et al: Increased rectal mucosal expression of interleukin-1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52: 523-526.
18. Barbara G, De Giorgio R, Deng Y, et al: Role of immunologic factors and cycloxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. Gastroenterology 2001; 120: 1729-1736.
19. Young P, Cash BD: Probiotic use in irritable bowel syndrome. Curr Gastroenterology Rep 2006; 8: 321-326.
20. Dunlop SP, Hebden J, Naesdal J, et al: Abnormal intestinal permeability in subgroups of diarrhea predominant irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1288-1294.
21. Attar A, Flourié B, Rambaud JC, et al: Antibiotic efficacy in intestinal bacterial overgrowth-related chronic diarrhea: a crossover randomized trial. Gastroenterology 1999; 117: 794-797.
22. Di Stefano M, Malservisi S, Veneto G, et al: Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000; 14: 551-556.
23. Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003: 98: 412-419.
24. O'Mahony L, McCarthy J, Kelly P, et al: A randomized, placebo-controlled, double-blind comparison of the probiotic bacteria Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom response and relationship to cytokines profiles. Gastroenterology 2005; 128: 541-550.
25. Kim HJ, Vazquez Roque M, Camilleri M, et al: A randomized controlled trial of a probiotic combination VSL #3 in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17: 687-696.
26. Buts JP, De Keyser N: Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci 2006; 51: 1485-1492.
27. McFarland LV: Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812-822.
28. Guslandi M, Mezzi G, Testoni PA: Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45: 1462-1464.
29. Dalmasso G, Cottrez, Imbert V, et al: Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 2006; 131: 1812-1825.
30. Nobaek S, Johansson ML, Molin G, et al: Alteration in intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 1231-1238.
31. Sen S, Mullah MM, Parker TJ, et al: Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002; 47: 2615-2620.
32. Niedzielin K, Kordecki H, Birkenfeld B: A controlled double-blind, randomized study of the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13: 1143-1147.
33. Saggioro A: Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 2004; 38(suppl 6): S104-S106.
34. O'Sullivan MA, O'Morain CA: Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000; 32: 294-301.
35. Bausserman M, Michail S: The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind placebo control trial. J Pediatrics 2005; 147:197-201.
36. Gawronska A, Dziechciarz P, Horvath A, et al: A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007; 25: 177-184.
37. Niv E, Naftali T, Hallak R, et al: The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome - a double-blind, placebo-controlled, randomized study. Clin Nutr 2005; 24: 925-931.
38. Whorwell PJ, Altringer L, Morel J, et al: Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101:1581-1590.
39. Maupas JL, Champemont P, Delforge M: Treatment of irritable bowel syndrome. Double-blind trial of Saccharomyces boulardii. Med Chir Digest 1983; 12: 77-79.
40. Bennani A: Essai randomise de Saccharomyces boulardii dans le traitement des colopathies fonctionnelles. L'Objectif Médical 1990; 73: 56-61.
41. Tsuchiya J, Barreto R, Okura R, et al: Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 2004; 5: 169-174.
42. Kajander K, Hatakka K, Poussa T, et al: A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled six-month intervention. Aliment Pharmacol Ther 2005; 22: 387-394.
43. Prantera C, Scribano ML, Falasco G, et al: Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51: 405-409.
44. Schultz M, Timmer A, Herfarth H, et al: Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004; 4: 5.
45. Bousvaros A, Guandalini S, Baldassano RN, et al: A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005; 11: 833-839.